Evidence map›Paper›PMID 24705439›Full record

ArticlePloS one2014

Predictive models of type 1 diabetes progression: understanding T-cell cycles and their implications on autoantibody release.

Majid Jaberi-Douraki, Massimo Pietropaolo, Anmar Khadra

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Majid Jaberi-DourakiDepartment of Physiology, McGill University, Montreal, QC, Canada.
Massimo PietropaoloLaboratory of Immunogenetics, University of Michigan, Ann Arbor, Michigan, United States of America.
Anmar KhadraDepartment of Physiology, McGill University, Montreal, QC, Canada.

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
IMPROVING PREDICTION OF IDDMR01DK053456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HERMAN, MARK A, REDONDO, MARIA JOSE · 1999 to 2021
$9.5M
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDMR01DK056200 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETROPAOLO, MASSIMO T · 2001 to 2009
$3.5M
Proteomics of Autoimmune Type 1 DiabetesR21DK073724 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIETROPAOLO, MASSIMO T · 2005 to 2006
$410k
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK053456NIDDK NIH HHS R01 DK056200NIDDK NIH HHS R01 DK53456NIDDK NIH HHS R01 DK56200NIDDK NIH HHS R21 DK073724
6 · The paper itself

Abstract

Defining the role of T-cell avidity and killing efficacy in forming immunological response(s), leading to relapse-remission and autoantibody release in autoimmune type 1 diabetes (T1D), remains incompletely understood. Using competition-based population models of T- and B-cells, we provide a predictive tool to determine how these two parametric quantities, namely, avidity and killing efficacy, affect disease outcomes. We show that, in the presence of T-cell competition, successive waves along with cyclic fluctuations in the number of T-cells are exhibited by the model, with the former induced by transient bistability and the latter by transient periodic orbits. We hypothesize that these two immunological processes are responsible for making T1D a relapsing-remitting disease within prolonged but limited durations. The period and the number of peaks of these two processes differ, making them potential candidates to determine how plausible waves and cyclic fluctuations are in producing such effects. By assuming that T-cell and B-cell avidities are correlated, we demonstrate that autoantibodies associated with the higher avidity T-cell clones are first to be detected, and they reach their detectability level faster than those associated with the low avidity clones, independent of what T-cell killing efficacies are. Such outcomes are consistent with experimental observations in humans and they provide a rationale for observing rapid and slow progressors of T1D in high risk subjects. Our analysis of the models also reveals that it is possible to improve disease outcomes by unexpectedly increasing the avidity of certain subclones of T-cells. The decline in the number of β-cells in these cases still occurs, but it terminates early, leaving sufficient number of functioning β-cells in operation and the affected individual asymptomatic. These results indicate that the models presented here are of clinical relevance because of their potential use in developing predictive algorithms of rapid and slow progression to clinical T1D.

Indexed as

Models, TheoreticalAutoantibodiesB-LymphocytesClone CellsCytotoxicity, ImmunologicDiabetes Mellitus, Type 1Disease ProgressionHumansPrognosisRecurrenceT-Cell Antigen Receptor SpecificityT-LymphocytesAutoantibodies

Identifiers

PMID24705439
PMCPMC3976292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.